Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/
Accepted 2025-09-11 00:00:00 ET · period of report 2025-09-09 · accession 0000950170-25-114293 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-09-11 | 2025-09-09 | DNTH | Savitz Ryan | CFO, CBO | S - Sale+OE | $35.00 | -20.0K | 0 | -100% | -$700.0K |
| DT | 2025-09-11 | 2025-09-09 | DNTH | Savitz Ryan | CFO, CBO | M - OptEx | $8.44 | +20.0K | 20.0K | New | +$168.8K |
| DT | 2025-09-11 | 2025-09-09 | DNTH | Savitz Ryan | CFO, CBO | M - OptEx | $0.00 | +20.0K | 104.8K | +24% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-09 | S | D | 20,000 | $35.00 | 0 | D | — | — | |
| 2 | Common | Common Stock | 2025-09-09 | M | A | 20,000 | $8.44 | 20,000 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-09-09 | M | A | 20,000 | $0.00 | 104,766 | D | $8.44 · — to 2032-06-06 | 20,000 Common Stock | (F2) The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |